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Abstract
Background:  Meningiomas are the most common intracranial neoplasias, representing a clinically and
histopathologically heterogeneous group of tumors. The neurofibromatosis type 2 (NF2) tumor suppressor is the
only gene known to be frequently involved in early development of meningiomas. The objective of this study was
to identify genetic and/or epigenetic factors contributing to the development of these tumors. A large set of
sporadic meningiomas were analyzed for presence of 22q macro-mutations using array-CGH in order to identify
tumors carrying gene dosage aberrations not encompassing NF2. The NF2 locus was also comprehensively studied
for point mutations within coding and conserved non-coding sequences. Furthermore, CpG methylation within the
NF2 promoter region was thoroughly analyzed.
Results: Monosomy 22 was the predominant finding, detected in 47% of meningiomas. Thirteen percent of the
tumors contained interstitial/terminal deletions and gains, present singly or in combinations. We defined at least
two minimal overlapping regions outside the NF2 locus that are small enough (~550 kb and ~250 kb) to allow
analysis of a limited number of candidate genes. Bialleinactivationo the NF2  gne was detected in 36% of
meningiomas. Among the monosomy 22 cases, no additional NF2 mutations could be identified in 35% (17 out of
49) of tumors. Furthermore, the majority of tumors (9 out of 12) with interstitial/terminal deletions did not have
any detectable NF2 mutations. Methylation within the NF2 promoter region was only identified at a single CpG site
in one tumor sample.
Conclusion: We confirmed previous findings of pronounced differences in mutation frequency between different
histopathological subtypes. There is a higher frequency of biallelic NF2 inactivation in fibroblastic (52%) compared
to meningothelial (18%) tumors. The presence of macro-mutations on 22q also shows marked differences between
fibroblastic (86%) and meningothelial (39%) subtypes. Thus, inactivation of NF2, often combined with the presence
of macro-mutation on 22q, is likely not as important for the development of the meningothelial subtype, as opposed
to the fibroblastic form. Analysis of 40 CpG sites distributed within 750 bp of the promoter region suggests that
NF2 promoter methylation does not play a major role in meningioma development.
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Background
Meningiomas are the most frequently occurring intracra-
nial tumors. Clinically treated meningiomas comprise
approximately 13–26% of all primary brain tumors [1].
Epidemiological studies indicate that ~90% of all menin-
giomas are asymptomatic [2]. The majority are benign,
slowly growing, solitary and sporadic tumors, but atypical
or malignant meningioma constitutes approximately
10% of all cases. Meningiomas are thought to be derived
from the arachnoid cap cells of the leptomeninges, which
is the covering of the brain and the spinal cord [1,3]. They
usually occur in the cranial meninges, but approximately
10% of tumors develop in the meninges covering the
spine. From histopathological and clinical points of view,
meningiomas are a heterogeneous group of tumors,
which are classified into 15 histopathological types with
WHO malignancy grades I–III [4].
Meningiomas was the first solid tumor to be characterized
as containing a specific genetic aberration, which is
monosomy 22 [5]. Since then, loss of genetic material
from chromosome 22 has been the most consistent aber-
ration, observed in up to 70% of tumors [6,7]. Meningi-
omas are closely associated with the genetic syndrome
neurofibromatosis type-2 (NF2). Approximately 50% of
NF2 patients suffer from meningiomas, making them the
second most frequent neoplasm associated with this
tumor syndrome [8-10]. In 1993, the neurofibromatosis
type 2 (NF2) tumor suppressor gene was characterized
from chromosome 22 [11,12]. Sporadic meningiomas
were therefore screened for mutations in the NF2 gene,
which was found to be frequently inactivated. There is,
however, a wide discrepancy in the reported mutation fre-
quency (20–60%) [7,13-18]. In fact, it has been shown
that meningiomas may be grouped into tumors with and
without mutations in the NF2 gene. These groups can also
be correlated with histopathological subtypes [15,17].
Tumors with mutations in the NF2 gene are often of the
transitional or fibrous subtype, commonly with allelic
losses on chromosome 22. Tumors without NF2  gene
mutations are predominantly of the meningothelial sub-
type, and allelic losses on chromosome 22 are less com-
monly observed in this subtype. Furthermore, the
meningothelial meningiomas are more often located in
the anterior parts of the skull base [19]. Transcriptional
silencing of the NF2 tumor suppressor by CpG methyla-
tion in meningiomas was recently tested by two research
groups, but the results were conflicting. Van Tilborg et al.
reported methylation in 1 out of 21 tumors, whereas
Lomas and colleagues reported a higher methylation fre-
quency (23 out of 88 cases) [20,21].
Despite almost 40 years of cytogenetic and molecular
genetic research, the NF2 tumor suppressor is still the only
specific gene which has been shown to be frequently
involved early in the development of meningiomas. There
is, however, a general consensus that other not yet charac-
terized loci are important for the development and/or
progression of these tumors [22-27]. Considering the clin-
ical and histopathological heterogeneity of meningiomas,
it is possible that alternative genetic mechanisms underlay
its tumorigenesis. There are reports of the loss of chromo-
some 22 as the primary consistent aberration in meningi-
omas, in the absence of mutations in the NF2  gene.
Moreover, young patients with constitutional ring chro-
mosomes and multifocal meningiomas have been charac-
terized. This highlights the possibility of an alternative
genetic etiology related to other genes located on chromo-
some 22 [23,28-30]. In addition, other sites in the
genome have been implicated in meningioma develop-
ment or progression [23]. Among these, aberrations of
chromosome 1 have been established as the second major
genetic factor for the initiation/progression of meningi-
omas and correlate with increased morbidity [31,32]. Fur-
thermore, the NF2 gene has also been excluded by linkage
analysis in one family with multiple meningothelial men-
ingiomas and ependymomas [33]. These various reports
suggest that there exist additional loci contributing to the
formation of meningiomas.
The rationale of this study was to perform a multilevel
analysis of mutations that include gene dosage aberra-
tions on chromosome 22, analysis of point mutations in
the NF2 locus, and profiling of the methylation status
within the NF2 gene promoter. We also intended to relate
our findings from chromosome 22 to the high resolution
DNA copy number variation in meningiomas of chromo-
some 1, which was recently reported [34].
Results and discussion
We analyzed a comprehensive series of sporadic meningi-
omas on multiple levels, i.e. for presence of "macro-muta-
tions" involving large scale aberrations of 22q using an
array-based approach and for "micro-mutations" within
the NF2 tumor suppressor gene. The latter involved anal-
ysis of point mutations within the mRNA encoding part of
this gene and within the conserved non-genic (CNGs)
sequences, which we have previously defined [35]. We
also comprehensively studied the promoter region of the
NF2 gene for CpG methylation.
Chromosome 22 DNA copy number profiling using array-
CGH
We studied 126 sporadic meningioma samples, compos-
ing a representative series of tumors operated on at a sin-
gle hospital in Sweden. All tumor samples studied were
analyzed previously using a lower resolution approach
[7,22,23,31,36]. The main rationale in this part of the
project was to identify tumors possessing gene dosage
aberrations of 22q which did not involve the NF2 locus.BMC Genomics 2007, 8:16 http://www.biomedcentral.com/1471-2164/8/16
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We carried out DNA copy number profiling using array-
CGH on a genomic microarray covering chromosome 22.
This array, containing 480 measurement points across the
sequenced part of this autosome, was developed and val-
idated previously [37]. Among the samples used for vali-
dation of this array was meningioma T24 DNA, which is
a well characterized tumor containing a large terminal
deletion of 22q and an additional approximately 150 kb
biallelic deletion involving EWSR1,  GAR22,  RRP22,
AP1B1, RFPL1 and NEFH genes [37,38]. On average, each
array-CGH experiment generated ~400 positively scored
data points from 22q.
Table 1 summarizes results obtained from DNA copy
number profiling of chromosome 22 and other results, as
well as relevant clinical information pertaining to the
studied patients. The predominant profile detected in 59
tumors was monosomy 22, which accounted for 47% of
meningiomas, and this result is consistent with previous
studies [7,22,23,31,36]. The biological consequence of
this very common aberration for the affected tumor cells
is one copy loss of all genes from 22q. The second cate-
gory comprised of16 tumors (13%) that were affected by
terminal deletions, interstitial deletions and gains, present
singly or in combinations (Figure 1A). This number is also
consistent with previous analysis using a loss of heterozy-
gosity (LOH) approach [7,22,23,31,36]. However, due to
a much higher density of data points used in the current
analysis, we were able to detect additional aberrations as
well as exactly define the breakpoints of all rearrange-
ments in samples which were characterized previously
using LOH. Figure 1A shows all 16 cases in detail, and
Figs. 2 and 3 display array-CGH profiles of 7 tumors pro-
viding new information. Tumor M64 (Figs. 1A and 2A)
disclosed a previously unknown biallelic deletion affect-
ing the NF2 gene. This was the only locus affected by a
homozygous deletion in the studied series of tumors,
which confirms the importance of the NF2 gene in men-
ingioma development. This fibroblastic meningioma has
an overall 22q profile consistent with a very large (> 30
Mb) terminal deletion of the long arm of chromosome
22. The second deletion affects only one clone (ID 151)
[GenBank: AC005529] and specifically targets the NF2
gene, thus inactivating its second allele in tumor cells.
Another interesting example is fibroblastic meningioma
M11, since it displays a terminal and multiple interstitial
deletions, all of which are located outside the NF2 locus
(Figs. 1A and 2E). Three of these deletions, located
towards the telomere of 22q, were previously character-
ized [39]. However, current analysis revealed an addi-
tional, smaller (~550 kb) deletion, encompassing 5
contiguous clones (ID 85–89) [GenBank: U07000–
AP000348], located on the centromeric side of the NF2
locus (Figures 1A, 1B and 2E). This tumor is intriguing
since no additional genetic/epigenetic aberration in the
NF2 gene could be detected in this sample (see below).
The vast majority of copy number aberrations of 22q in
meningiomas point to inactivation or a decreased gene
dosage. However, in two tumors (M109 and M96, Figs 1A,
2C and 3A) we were able to detect a low copy number
gain. For instance, tumor M109 displays a combination of
low copy number gain in the centromeric part of 22q and
a large terminal deletion (Figure 2A). A minimum over-
lapping region of gain is approximately 3.8 Mb (clone ID
11–48) [GenBank: AC006285 – AC007957] and is
located in 22q11. The importance of these gains for men-
ingioma tumorigenesis is difficult to judge, as they are not
frequent events. One possible explanation is that these
gains reflect cell-specific chromosomal instability of
22q11, since this region is rich in intra-chromosomal seg-
mental duplications and is prone to rearrangements lead-
ing to several genetic disorders.
All samples displaying aberrations other than monosomy
22 are graphically summarized in Fig 1A. This analysis
enables the discrimination of several minimal overlap-
ping deleted regions which should be studied further. Two
of these regions, named as R1 (~550 kb) and R2 (~250
kb) are small enough to allow for detailed analysis of a
limited number of candidate genes (Figs. 1B and 1C). The
breakpoint cluster region (BCR) gene is one interesting
candidate located in R1. This gene is located at the site of
the chromosome 22 breakpoint generating the Philadel-
phia chromosome (9;22) translocation that creates the
BCR/ABL fusion gene found in chronic myeloid leukemia
and acute myeloid leukemia. The normal BCR gene was
reported to have a serine/threonine kinase activity [40].
Another candidate gene located within R1 is the RGR
oncogene. This gene was originally identified as a fusion
protein which can promote tumor development in nude
mice, but has also displayed oncogenic properties when
not in the fusion form [41]. The RGR gene has frequently
been found to be altered in human T-cell malignancies
[42]. The zinc finger protein encoding gene ZCWCC1,
located within R2, may also be a candidate for further
investigation. The relative weakness of the R1 and R2
regions is that they are defined by rare cases with small
deletions. There is therefore a possibility that the latter
chromosome 22 aberrations are neutral "passenger muta-
tions", with little consequence to tumorigenesis. Yet
another apparent, large candidate region is located
towards the telomere of 22q, starting from clone ID 390.
This segment is affected by hemizygous deletion in all but
one (M114) of the studied tumors which disclosed gene
copy number imbalances of chromosome 22.
The third major category of tumors (51 cases, 40%) was
composed of samples that did not display detectable
changes in gene dosage on 22q (Table 1, "No Aberration
Detected"; NAD) despite the high average resolution (~75B
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Table 1: Genetic alterations in one hundred meningiomas.
Sample ID Subtype1 CH3 NF2 gene mutations DNA copy number profiles4
Position Mutation2 Assumed effect3 Chromosome 22 Chromosome 1 Loss of non-22 genes5
M26 A Ex 2 227_240del Lys76fs Monosomy Monosomy D1, S1A, S1B
M71 A Ex8 810+2T>C Abn. Spl. Monosomy 1p, 120.8 Mb TD D1, P2A, S1A, S1B
M38 A Ex6 573del; 575_581del Trp191fs Monosomy 1p 107.9 Mb TD P1B, P2A, S1A, S1B
M43 A Ex12 1185del Lys396fs Monosomy 1p 120.3 Mb TD, 4.4 Mb A
M46 A Ex8 810+2T>C Abn. Spl. NAD NAD
M33 A NAD 30.6 Mb TD [AC009516-AC002055] 1p, 90.2 Mb TD, 45.8 Mb ID
M9 A NAD NAD NAD
M20 A NAD NAD NAD
M13 F Ex 2 240+2T>C Abn. Spl. Monosomy 1p, 142.9 Mb TD P2A, S1A, S1B
M88 F Ex4 364-1G>A Abn. Spl. Monosomy 1p 84.1 Mb TD; 1q 4.6, 7.1 Mb 
IDs, 12.5 Mb TD
P2A
M3 F Ex 2 240+2T>C Abn. Spl. Monosomy 1p 119.8 Mb TD
M14 F Ex3 249del His84fs Monosomy 1p 120.2 Mb TD
M15 F Ex8 683del Lys228fs Monosomy 1p 116.0 Mb TD
M39 F Ex8 810+1G>A Abn. Spl. Monosomy NS
M42 F Ex10 995del Lys332fs Monosomy NS
M70 F Ex6 599+1G>A Abn. Spl. Monosomy NS
M91 F Ex 2 154del Arg52fs Monosomy NS
M102 F Ex9 865A>T Lys289X Monosomy NS
M115 F Ex7 634C>T Gln212X NAD 1p 119.6 Mb TD
M646 F NAD 30.4 Mb TD [AC008079-AC002055], NF2 biallelic del 
[AC005529]
1p 98.8 Mb ID; 1q 24.2 Mb ID P1B, P2A
M66 F NAD Monosomy 1p 118.1 Mb TD P2A
M117 F NAD 0.55, 2.8, 4.5 Mb IDs [U07000-AP00034, AC005004-Z69907, 
AL022311-Z83851]; 5.9 Mb TD [Z93244-AC002055]
1p 116.8 Mb TD, 3.6 Mb A
M32 F NAD 5.3 Mb ID [AL022329-AL022336], 15.2 Mb TD [AL009049-
AC002055]
NS D1
M4 F NAD Monosomy NAD
M29 F NAD Monosomy NS
M41 F NAD Monosomy NS
M92 F NAD Monosomy NS
M114 F NAD 18.0 Mb ID [AP000525-Z68324] NS
M119 F NAD NAD NS
M10 M Ex13 1341-2A>G Abn. Spl. Monosomy 1p 120.3 Mb TD P2A
M23 M Ex3 241-2A>C Abn. Spl. Monosomy 1p 120.9 Mb TD P2A
M67 M Ex4 432C>A Tyr144X Monosomy 1p 120.8 Mb TD P2A
M98 M Ex14 1519_1520del Phe507fs Monosomy NAD D1, P2A, S1A, S1B
M57 M Ex 2 133_144 del Asp45fs Monosomy NS
M72 M Ex7 634C>T Gln212X Monosomy NS
M40 M NAD Monosomy 1p 164.9 Mb TD P1B, P2AB
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) M76 M NAD Monosomy 1p 142.7 Mb TD P2A
M105 M NAD Monosomy 1p 116.3 Mb TD P1B, P2A
M348 M NAD 20.0 Mb TD [AC004542-AC002055] 1p 102.8 Mb ID
M44 M NAD Monosomy 1p 85.4 Mb TD
M101 M NAD 25.1 Mb ID [AP000525-AL035450], 7.9 Mb TD [AL049758-
AC002055]
Monosomy, 1p 2.1 Mb R
M30 M NAD Monosomy NAD D1, P2A
M112 M NAD NAD 1p 114.2 Mb TD
M2 M NAD NAD NAD
M5 M NAD NAD NAD
M77 M NAD NAD NAD
M82 M NAD NAD NAD
M45 M NAD NAD NS
M51 M NAD NAD NS
M54 M NAD NAD NS
M61 M NAD NAD NS
M63 M NAD NAD NS
M65 M NAD NAD NS
M69 M NAD NAD NS
M86 M NAD NAD NS
M95 M NAD NAD NS
M99 M NAD NAD NS
M107 M NAD NAD NS
M108 M NAD NAD NS
M111 M NAD NAD NS
M116 M NAD NAD NS
M120 M NAD NAD NS
M93 P Ex8 810G>T Glu270Asp Monosomy 1p 114.3 Mb ID P2A
M229 PE x 1 3 ,  
inter1
1390del; 28309611 
C>A
Ala464fs, 
unknown
Monosomy NS
M62 P NAD Monosomy NS
M21 P NAD NAD NS
M60 T Ex14 1519_1528del Phe507fs Monosomy 1p 118.2 Mb TD P2A
M1 T Ex7 650del Tyr217X Monosomy 1p 65.0 Mb TD
M31 T Ex13 1325del Ala451fs Monosomy 1p 53.2, 36.3 Mb IDs
M58 T Ex 2 115-3G>C Abn. Spl. 30.1 Mb TD [AC007050-AC002055] 1p 120.2 Mb TD
M90 T Ex3 241-2A>G Abn. Spl. 20.1Mb ID [AP000525-AL079295], 13.4 Mb TD [AL049850-
AC002055]
1p 83.3 Mb TD
M96 T Ex12 1175G>T Glu392X 2.0 Mb ID [AP000525-AC007666], 5.4 Mb A [AC006285-
AC000102], 27.5 Mb TD [U07000-AC002055]
1p 43.3 Mb TD, 1q 69.9 Mb TD
M52 T Ex4 431_432insAA Tyr144X Monosomy NS P1B
M113 T Ex4 377del Leu127X Monosomy NAD D1, P1B, P2A, S1A, 
S1B
M18 T Ex12 1198C>T Gln400X Monosomy NS
Table 1: Genetic alterations in one hundred meningiomas. (Continued)B
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M37 T Ex8 745_755del Arg249fs Monosomy NS
M48 T Ex 1 36_37del Leu14fs Monosomy NS
M75 T Ex8 750del Thr251fs Monosomy NS
M87 T Ex4 436G>A Val146Ile NAD NS
M56 T NAD Monosomy 1p 116.5 Mb TD P2A
M85 T NAD Monosomy 1p 108.2 Mb TD P2A
M109 T NAD 5.7 Mb A [AC006548-AC007957], 30.6 Mb TD [AC009516-
AC002055]
1p 120.2 Mb TD
M27 T NAD 15.5Mb ID [AP000525-AC005005], 14.1 Mb TD [AL049749-
AC002055]
NS
M59 T NAD Monosomy NS
M68 T NAD Monosomy NS
M94 T NAD Monosomy NS
M97 T NAD Monosomy NS
M25 T NAD NAD 1p 98.7 Mb TD
M117 T NAD NAD 1p 36.1 Mb TD
M10410 T+ N A D N A D N S
M8 T NAD NAD NS
M12 T NAD NAD NS
M17 T NAD NAD NS
M35 T NAD NAD NS
M55 T NAD NAD NS
M89 T NAD NAD NS
M103 T NAD NAD NS
M78 U Ex10 999+1G>T Abn. Spl. Monosomy 1p 3.8 Mb TD
M79 U NAD NAD 1p 39.1Mb ID, 1q 41.3Mb TD
M83 U NAD NAD NS
1 Tumors are grouped according to histopathological subtypes. Abbreviations: A, Anaplastic; F, Fibroblastic; M, Meningothelial; P, Psammomatous; T, Transitional and U, Unclassified.
2 Position of the mutations according to numbering of the cDNA sequence, nucleotide number one is the A in the ATG translation initiation codon [GenBank:AF369658]. Abbreviations: substitution, >; 
deletion, del; insertion, ins; No Aberration Detected, NAD. Donor splice site mutations indicated by the last nucleotide of the preceding exon, a plus sign and position in the intron (e.g. 240+2T>C). 
Acceptor splice site mutations denoted by the first nucleotide of the following exon, a minus sign and position in the intron (e.g. 241-2A>C).
3 Amino acid number one is the translation initiator Methionine. Abbreviations: translation termination codon, X; frame shift, fs; abnormal splicing, Abn. Spl.
4 Data from copy number imbalances on chromosome 1 were previously published [34]. Abbreviations: Terminal Deletion, TD; Interstitial Deletion, ID; Amplification/gain, A; Not Studied, NS; No 
Aberration Detected, NAD; Retained segment R. Genbank accession numbers in squared brackets.
5 Loss of non-chromosome 22 clones spanning the DAL1, D1; PTCH2A, P2A; PTCH1B, P1B; SUFU1A, S1A; and SUFU1B, S1B genes.
6 M64 displays a homozygous deletion of the NF2 gene.
7 M11 demonstrates multiple deletions not affecting the NF2 gene.
8 M34 displays a terminal deletion not affecting the NF2 locus.
9 M22 presents two mutations in the NF2 locus, in exon 13 and in the CNG inter1. The position of the inter1 mutation is according to numbering on chromosome 22 (UCSC Homo sapiens Genome 
Browser, assembly July 2003). Ten bases on each side of the mutation: agcaaagagaCaaattaccca.
10 Methylation of a single CpG site in the intron 1 of the NF2 gene in ~40% of DNA molecules.
Table 1: Genetic alterations in one hundred meningiomas. (Continued)BMC Genomics 2007, 8:16 http://www.biomedcentral.com/1471-2164/8/16
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Summary of array-CGH profiles for chromosome 22 insporadic meningioma Figure 1
Summary of array-CGH profiles for chromosome 22 insporadic meningioma. A) Detailed summary of all complex 
aberrations. Deletions and gains are mapped according to the clones present on the chromosome 22 minimal tiling path array. 
Chromosome 22 clones are grouped in bins of 10 along the y-axis. The panel of tumors which displayed complex aberrations 
of chromosome 22 is shown from left to right. The red, yellow and blue boxes denote hemizygous deletion, biallelic deletion 
and gain, respectively. The horizontal dashed line displays the approximate position of the NF2 gene in relation to the measure-
ment points on the chromosome 22 minimal tiling path array. The table below details the clone ID's at which the deletion/gain 
starts and finishes. Smallest regions of overlapping deletions are highlighted with grey lines (R1 and R2) and genes present 
within these regions are shown to the left. Tumor names highlighted in bold are displayed in more detail in other figures. B) 
Detailed view of candidate region 1 (R1) with gene and clone information presented according to the positions on chromo-
some 22 sequence (UCSC Homo sapiens Genome Browser, assembly July 2003). C) Detailed view of candidate region 2 (R2) 
with gene and clone information presented according to the positions on chromosome 22 sequence (UCSC Homo sapiens 
Genome Browser, assembly July 2003).
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Array-CGH profiles of chromosome 22 in tumors displaying complex aberrations Figure 2
Array-CGH profiles of chromosome 22 in tumors displaying complex aberrations. The chromosome 22 array-
CGH plots consist of 480 chromosome 22 clones ordered from centromere to telomere and 9 chromosome X controls 
between the vertical lines, as well as 31 non-chromosome 22 controls plotted on the right hand side. The y-axis displays the 
raw fluorescent intensity ratios for each clone on the genomic array. The position of the NF2 gene is highlighted with the ver-
tical grey bar. A) Array-CGH profile of case M64 displaying a single copy loss of the majority of the chromosome with a bial-
lelic deletion encompassing a single measurement point (clone ID 151) [GenBank:AC005529], specifically targeting the NF2 
gene (highlighted by a grey circle). Encircled clones centromeric of NF2 display fluorescent ratio consistent with two copies; 
clone IDs 61–63 [GenBank:D87000–D87003] (previously reported Copy Number Polymorphism, CNP) and clone IDs 99–100 
[GenBank:AL049759–AL050312]. Clone ID 400 [GenBank:Z84478] positioned towards the telomere, also exhibit two gene 
copies (highlighted by a circle). Control clone derived from chromosome 10 encompassing SUFU1B gene presents with one 
copy loss (highlighted by a circle). B) Array-CGH profile of case M32 displaying an interstitial deletion encompassing the NF2 
gene and a terminal deletion. Clones spanning the DAL-1 gene on chromosome 18 and clones spanning the PTCH1B locus on 
chromosome 9 display a fluorescent ratio consistent with a one copy loss are highlighted by a circle. C) Case M109 displaying 
a gain spanning clone IDs 5–48 [Genbank:AC006548–AC007957] followed by a large terminal deletion covering clones 49–480 
[Genbank:AC009516–AC002055]. Two CNPs are positioned at clone IDs 13–15 and 63 [Genbank: AC008079–AC008132 and 
D87003] and are indicated by circles. D) Meningioma M101 displaying a large one copy loss for the majority of the chromo-
some apart from a region encompassing clone IDs 348–366 [GenBank:AL080242–Z82176] and a CNP spanning clone IDs 60–
61 [GenBank:D88269–D87000]. E) Detection of multiple interstitial deletions outside the NF2 region, spanning clone IDs 85–
89 (R1, highlighted by a circle), 181–262 and 311–360 [GenBank: U07000–AP000348, AC005004–Z69907 and AL022311–
Z83851] and a terminal deletion covering clone IDs 390–480 [GenBank:Z93244–AC002055] in case M11. A CNP spanning 
clone IDs 14–15 [GenBank:AC008132–AC008103] is highlighted by a circle.
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kb per data point). There may be several possible explana-
tions for these results. One possibility is that additional
genes on 22q (other than NF2  tumor suppressor) are
important for meningioma development and these are
mutated by alternative mechanisms, such as point muta-
tion or epigenetic silencing. Another explanation might
be that this subset of samples involves an alternative tum-
origenic pthway which does not involve chromosome 22-
located genes.
The current version of the chromosome 22 array has been
supplemented with additional non- 22q-derived genomic
clones from other chromosomes, which encompass genes
(e.g. PTCH2A, PTCH1B, SUFU and DAL1 genes) of poten-
tial interest in the fields of meningiomas and brain
tumors in general. The complete list of these additional
clones is provided in additional file 1. Table 1 shows the
samples in which loss of DNA copy number was detected
for some of these loci. The highest rate of loss detected was
at the PTCH2A locus on 1p34.1, which displayed a rate of
loss of 18%. The other loci, namely DAL-1, PTCH1B,
SUFU1A  and  SUFU1B, displayed a level of DNA copy
number loss of 6%, 5%, 6% and 6%, respectively. We also
detected DNA copy number losses in a number of non-
chromosome 22-derived control clones. The most fre-
quently deleted control clones were those derived from
Detection of cellular or genetic heterogeneity in meningioma samples Figure 3
Detection of cellular or genetic heterogeneity in meningioma samples. The array-CGH plots follow the same gen-
eral scheme as for Figure 3. However, the data points are shaded in grey and a trend line (with a moving average of 10 data 
points) is shown, which highlights the difference in fluorescent ratio levels along the chromosome. A) Identification of genetic 
heterogeneity in meningioma sample M96 which displays 3 different fluorescent ratio values across chromosome 22. The clone 
IDs and Average Normalized Inter Locus Fluorescence Ratio (ANILFR) for each of these are 1–15, 0.95; 16–84, 1.1 and 85–
480, 0.83, respectively. B) Array-CGH profile of a complex set of aberrations on chromosome 22, which suggest genetic/cellu-
lar heterogeneity within the tumor M90. The regional shifts in fluorescent ratio across chromosome 22 are as summarized 
with the clone IDs and their ANILFR value; 1–23, 0.95; 24–66, 0.90; 67–214, 0.76; 215–284, 0.88; 285–303, 1.09; 304–326, 
0.87; 327–480, 0.76. The non-chromosome 22 autosomal controls have an ANILFR value of 1.00, since this value was used to 
normalize all values across the genomic array.
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chromosomes 1 and 3, suggesting the likely importance of
other regions of the genome in meningioma develop-
ment/progression.
Mutation analysis of NF2 exons and evolutionarily 
conserved non-genic sequences (CNGs)
Inactivating micro-mutations in the NF2 tumor suppres-
sor gene are found in meningiomas of all histopathologi-
cal subtypes and malignancy grades and are thought to be
an early event in tumorigenesis [43]. However, large dif-
ferences (20–60%) of mutation frequency in sporadic
meningiomas were previously reported [7,13-18]. Our
rationale was to reassess the mutation frequency of NF2,
especially when combined with very high resolution
array-CGH analysis of these tumors. The rationale was
also to test the hypothesis that mutations might be
located in evolutionarily well conserved non-genic
sequences within introns or in the 5' promoter region of
the  NF2  gene, in addition to mutations in the exons.
Comparisons of the orthologous genomic sequence from
the NF2 locus derived from five species (human, baboon,
mouse, rat and pufferfish) were previously performed in
order to identify CNGs that might be of functional impor-
tance for the NF2 gene [35]. The exonic sequence of the
NF2 gene constitutes ~2.7% of this locus. When applying
a threshold of 70% sequence identity over >100 bp of gap-
free alignment in comparisons between human and
mouse, the resulting level of extra-exonic conservation
was 3.8%. We selected CNGs for mutational analysis that
displayed a similar level of evolutionarily conservation as
the protein coding sequence. In total, 17.5 kb was
sequenced in 100 tumors, which included all 17 exons,
the highly conserved exon flanking sequences and seven
CNGs not contiguous with exons (Figure 4A). Four of the
CNGs were positioned upstream of exon 1 and the
remaining three CNGs were located in introns 1, 4 and 10.
Thirty-nine alterations were identified in 100 analyzed
samples (Tables 1, 2 and 3). Fifteen mutations caused
frame-shifts, twelve altered the acceptor- or donor-splice
sites, nine were nonsense, two were missense and one
mutation occurred in the inter1 CNG. None of the identi-
fied mutations were present in the corresponding periph-
eral blood DNA. Thirty-five of these mutations were
accompanied by a macro-mutation on the other allele,
either through monosomy or terminal/interstitial dele-
Overview of the NF2 locus analyzed for point mutations and methylation of CpG dinucleotides Figure 4
Overview of the NF2 locus analyzed for point mutations and methylation of CpG dinucleotides. A) Illustration of 
the NF2 gene displaying exons (black boxes) and conserved non-genic sequences (CNGs) (green boxes) that were analyzed for 
point mutations. Gene orientation is displayed with an arrow next to the gene name. The scale is according to sequence posi-
tion on chromosome 22 in million base pairs (Mb) (UCSC Homo sapiens Genome Browser, assembly July 2003). B) Schematic 
view of the CpG sites in the 5' part of the NF2 gene that were analyzed for methylation. The 40 sequenced CpG sites were 
located between positions -591 and +166 bp (position +1 refers to transcriptional start site). A single methylated CpG site was 
detected in tumor M104 at position +120 in ~40% of DNA molecules (displayed as a red filled circle).
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tions. Overall, we could detect mutations consistent with
biallelic inactivation of the NF2 tumor suppressor gene in
36% of meningiomas (Table 3). However, in three cases
(M46, M115 and M87) no second inactivating mutation
could be identified. Considering what is known to date
about the NF2  gene mutational spectrum in different
tumors, it can be assumed that at least two of the latter
three mutations (M46 – aberrant splicing and M115 –
nonsense mutation) are pathogenic. These types of muta-
tions are, however, usually combined with the second
inactivating hit on the remaining normal allele of the gene
[13,44-47]. The third aberration is a missense mutation
(tumor M87, exon 4, 436 G>A, Val-146-Ile, Table 1),
which is possibly introducing a dysfunction to the N-ter-
minal FERM domain (residues 1–302 of the protein,
plasma membrane binding domain) of the protein. Mer-
lin/schwannomin provides a link between the cytoskele-
ton and plasma membrane and interacts with the actin
cytoskeleton through binding sites in its FERM domain
[48,49]. Thus, there exists a possibility of this missense
mutation exerting a sufficiently strong dominant negative
effect on the protein function, which does not necessitate
the presence of the second hit NF2 gene inactivating event
in this tumor. The three tumors discussed above (M46,
M115 and M87) allow us to estimate our false negative
detection rate of mutations in the NF2 gene. We can spec-
ulate that, in at least two and a maximum of three of the
studied tumors, we could expect the second hit NF2 gene
mutation to be present, but we were unable to detect it.
Assuming the above reasoning to be correct, our false neg-
ative rate of micro-mutation detection is between 5.1 –
7.6%.
In case M22 we identified two tumor-specific micro-muta-
tions, one mutation causing a frame shift in exon 13 intro-
ducing a premature stop codon and the second being a
mutation in the inter1 CNG element. Inter1 is situated
approximately 15 kb upstream of the NF2 gene (Figure
4A). It displays sequence conservation between human
and pufferfish, which are evolutionarily very distant spe-
cies [35], suggesting that inter1 may possess functional
properties. Details on the exact position of the inter1
mutation on chromosome the 22 sequence are shown in
Table 1. The tumor-specific mutation in inter1 CNG is one
of three changes present in M22, as this tumor also con-
tains monosomy 22. Thus, we may speculate that three
hits are affecting the NF2 gene. An alternative explanation
is that one of these mutations has little consequence to the
normal function of the NF2 gene.
Methylation profiling of the NF2 promoter region by 
bisulfite modification followed by pyrosequencing
Methylation of promoter associated CpG-islands is
known as a possible mechanism for inactivation of tumor
suppressor genes in a variety of human cancers. It has also
been suggested as a mechanism of repressing transcription
of the NF2 gene in schwannomas [50] and in meningi-
omas [21]. Methylation of other cancer related genes
(GSTP1,  THBS1,  CDKN2A,  CDH1,  BRCA1,  p14ARF  and
RB1) has also been reported to be associated with malig-
nant progression of meningiomas [20,51,52]. We used an
established method of bisulfite treatment of tumor DNA
followed by Pyrosequencing (Biotage, Uppsala, Sweden)
which allows detection and semi-quantitative estimation
of the degree of methylation at the selected CpGs [53,54].
Two overlapping PCR products of 339 bp and 550 bp cov-
ered ~750 bp of the upstream promoter region, the first
exon and approximately 70 bp of intron 1, immediately
downstream of the first exon (Figure 4B). These two prod-
ucts were Pyrosequenced with 8 sequencing primers. In
total, 40 CpG sites were sequenced, between positions -
591 and +166 bp (position +1 refers to transcriptional
start site). This analysis allowed interrogation of up to 11
CpG sites per assay, distributed over 79 bp and with a
maximum of 60 dispensations of nucleotides (additional
file 2). Methylation was identified in only one tumor sam-
ple (M104), at a single CpG site at position +120, in ~40%
of DNA molecules in this tumor (Figure 4B). Kino et al.
reported a 70 bp region (-591 to -522) essential for NF2
expression in schwannomas [50]. Three CpG sites within
this region (at positions -591, -586 and -581) appeared to
be of particular importance for silencing of the NF2 gene
upon methylation in schwannomas. We paid particular
attention to these CpG sites but no methylation was
detected. In summary, upon comprehensive analysis of 40
CpG sites, we conclude that methylation does not play a
major role in the silencing of the NF2 gene in meningi-
omas. These results are in accordance with a report by van
Table 2: Chromosome 22 DNA copy number status and NF2 gene mutations in a subset of 100 sporadic meningiomas.
NF2 gene
Chr. 22 status Point mutation No point mutation Total
Monosomy 32 17 49
NAD1 33 6 3 9
Interstitial/terminal deletion 3 9 12
Total 38 62 100
1 No Aberration Detected, NADBMC Genomics 2007, 8:16 http://www.biomedcentral.com/1471-2164/8/16
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Tilborg et al [20] although contradicting the results from
Lomas et al. [21].
Summary of macro- and micro-mutations on chromosomes 
22 and 1 in meningiomas
We observed pronounced differences of the NF2  gene
mutation frequency between different histopathological
subtypes of meningiomas (Table 3). There was a clear
trend towards an increased frequency of the biallelic NF2
gene inactivation in meningothelial, transitional and
fibroblastic subtypes which were 6 out of 33 tumors
(18%), 12 out of 31 tumors (39%) and 11 out of 21
tumors (52%), respectively. Based on these results, we
may speculate that the biallelic inactivation of the NF2
gene is not as important for the development of the
meningothelial subtype of meningioma, when compared
to the transitional and fibroblastic tumors. A related trend
was even more pronounced, when the frequencies of large
chromosome 22 deletions were correlated to the three
above mentioned histopathological subtypes of meningi-
oma. The presence of large hemizygous deletions showed
marked differences between the meningothelial, transi-
tional and fibroblastic subtypes, comprising 13 out of 33
cases (39%), 20 out of 31 cases (65%) and 19 out of 21
cases (90%), respectively. It should be stressed here that
15 out of 19 fibroblastic meningiomas, which displayed
gene dosage imbalances on 22q, were monosomy 22
cases. The three remaining tumors (M64, M32, and
M114) all showed a minimum loss of 18 Mb of 22q. It
may thus be hypothesized that one copy loss of genes
located within the 18 Mb on 22q is important for genera-
tion of the fibroblastic phenotype of cells.
More than half (61%) of the meningothelial cases were
among the category of tumors with both chromosome 22
copies retained. One possible explanation for this finding
is that meningothelial tumors more frequently harbor
mutations in additional genes that are located outside
chromosome 22. Our results correlate well with previous
studies by Wellenreuther et al. [15] as well as with Evans
and colleagues [17] that identified NF2 gene mutations in
4/26 (15%) and 1/20 (5%) of meningothelial tumors.
The above results from DNA level analysis are supported
by analysis of merlin/schwannomin protein expression,
which show normal expression in the greater part of
meningothelial tumors, but severely reduced expression
levels in the majority of fibrous and transitional meningi-
omas [55-57]. Furthermore, correlation between tumor
localization and histological subtype was previously
reported. The majority of meningiomas with no chromo-
some 22 aberrations were localized in the anterior skull
base and were predominantly meningothelial [19]. Taken
together, these results might suggest that cellular origin
plays a role in the genetic pathways which are operative
during tumor formation of meningiomas. In the context
of our results from chromosome 22, it is interesting to cor-
relate this to the data obtained from chromosome 1, as
genetic aberrations affecting these two autosomes are the
most frequent genetic abnormalities in meningiomas
[31,36]. Furthermore, aberrations of chromosome 1 are
also related to recurrence-free survival from the disease
[31]. We have recently completed a high resolution anal-
ysis of chromosome 1 using the same tumor series [34]
and 49 of the samples were studied with similar resolu-
tion on both chromosomes (Table 1). There is a strong
relationship between changes on both chromosomes,
with 67% of samples showing concurrent aberrations.
These results clearly indicate the need for a genome-wide
and high-resolution array-based characterization of chro-
mosomal aberrations in meningiomas.
Conclusion
One objective of this study was to identify the maximum
number of tumors displaying copy number aberrations of
Table 3: NF2 gene mutation frequencies in meningiomas of different histological subtypes.
Histological subtype Total no. NF2 gene mutation 
frequency1
Chr. 22 deletions affecting the 
NF2 gene
Biallelic inactivation of the 
NF2 gene
Meningothelial 33 6/33 (18%) 13/33 (39%) 6/33 (18%)
Transitional 31 13/31 (42%) 20/31(65%) 12/31(39%)
Fibroblastic 21 11/21 (52%) 18/21 (86%)4 11/21 (52%)5
Anaplastic 8 5/8 (61%)2 5/8 (61%) 4/8(50%)
Psammomatous 4 2/4 (50%)3 3/4 (75%) 2/4 (50%)
Unclassified 3 1/3 (33%) 1/3 (33%) 1/3 (33%)
Overall 100 39 60 36
1 The methylation status of NF2 gene promoter in tumor M104 is not included.
2 The two micro deletions (1 bp and 7 bp) detected in M169 within exon 12 are considered as one.
3 Two point mutations were detected in M22, only one is used for calculations.
4 Fifteen of the 18 fibroblastic meningiomas that display deletions on chromosome 22 are monosomy cases. The three remaining tumors (M64, 
M32, and M114) all disclose a minimum of 18 Mb deletion of 22q.
5 Case M64 (biallelic deletion affecting the NF2 gene) is not included in this calculationBMC Genomics 2007, 8:16 http://www.biomedcentral.com/1471-2164/8/16
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22q not encompassing the NF2 locus. From the category
of tumors displaying terminal- and interstitial-deletions
we identified at least two minimal overlapping candidate
regions outside the NF2 locus. These regions allow analy-
sis of a limited number of candidate genes. Interesting
candidates in these regions include the BCR gene, impli-
cated in chronic myeloid leukemia and acute myeloid
leukemia; the RGR oncogene involved in RAS-signaling
[58] and found to be altered in human T-cell malignancies
[42]; and the zinc finger protein encoding gene ZCWCC1.
One additional candidate region starts at clone ID 390
and extends toward the telomere (Fig 1A). This segment is
hemizygously deleted in all but one (M114) of the studied
tumors with 22q gene copy number imbalances.
We assessed the point mutation frequency of NF2 in com-
bination with array-CGH of 22q. The rationale was to test
the hypothesis that mutations also may be located in evo-
lutionarily well conserved non-genic sequences within
introns or in the 5' promoter region, in addition to muta-
tions in the exons. We identified 39 point mutations in
100 tumors. In one single case (M22), there were three
tumor-specific mutations detected; a point mutation in
the CNG inter1, a nonsense mutation in exon 13 and
monosomy 22. Inter1  displays sequence conservation
between human and pufferfish, suggesting that it may
possess functional properties. However, the fact that the
inter1 mutation represented one out of three genetic alter-
ations in this tumor, and that we only identified a single
mutation in one CNG, suggests that this is not a major
mechanism for inactivation of the NF2 gene. We also ana-
lyzed the methylation status of NF2 promoter associated
CpGs in order to examine if this mechanism is associated
with repressing NF2 transcription in sporadic meningi-
omas. We identified methylation in only one tumor sam-
ple (M104), at a single CpG site (Figure 4B). Thus, we
conclude that methylation is unlikely to play a major role
in silencing of the NF2 gene in meningioma.
Profound differences in mutation frequency were
observed between various histopathological subtypes of
tumors. There was a considerably higher frequency of
biallelic NF2 inactivation in fibroblastic (52%) compared
to meningothelial (18%) tumors. The presence of 22q
copy number imbalances were also more common in the
fibroblastic (86%) compared to the meningothelial
(39%) subtype. Thus, inactivation of NF2 combined with
the presence of macro-mutation on 22q, might not be as
important for the development of the meningothelial
subtype, as opposed to the fibroblastic form.
Chromosome 1 genetic abnormalities are frequently
observed in meningiomas [31,36]. Forty-nine of the sam-
ples studied here were also previously analyzed for gene
dosage aberrations on chromosome 1 by array-CGH [34].
We observed a strong correlation between changes on
both chromosomes, with 67% of samples showing con-
current aberrations. A genome-wide and high-resolution
copy number analysis could contribute to identify addi-
tional genetic alterations involved in tumor development,
especially for the meningothelial subtype, which does not
commonly display NF2 and 22q alterations.
Methods
Patient samples
Tumor tissue and matched samples of peripheral blood
were collected and DNA was isolated using standard
methods [59]. Samples were obtained from the Dept. of
Neurosurgery, Karolinska Hospital, Stockholm, Sweden.
All analyzed tumor samples were reported previously in
various studies [7,22,23,31,34,36]. Ethical approval was
granted from the Research Ethics Committee, Faculty of
Medicine, Uppsala University. Copy number profiling of
chromosome 22 was performed on 126 sporadic menin-
giomas and this sample set comprised 39 meningothelial,
38 transitional, 28 fibroblastic, 9 anaplastic, 6 psam-
momatous, 1 angiomatous and 5 tumors of unclassified
histopathological subtype. For the analysis for point
mutations and methylation in the NF2 gene promoter, we
used a subset of 100 tumor DNA samples (Table 1 and
additional file 3).
DNA copy number profiling using the chromosome 22 
genomic microarray
The genomic microarray used to assess DNA copy number
status of chromosome 22 has been described previously
[37]. In brief, 480 genomic clones derived from the mini-
mal tiling path of chromosome 22, 8 control clones from
chromosome X and 30 non-chromosome 22 autosomal
control clones were isolated and grown in bacterial cul-
tures overnight. The clone DNA (cosmid, fosmid, BAC
and PAC) was purified using Qiagen kits and quantified
using the picoGreen assay (Molecular Probes, Inc.,
Eugene, OR). All clone DNA were verified using STS PCR.
The prepared clone DNA stock was amplified by DOP-
PCR [60]. A second round of PCR on the DOP-PCR prod-
ucts using an amino linked universal primer was per-
formed and amplification products were printed in
quadruplicate on CodeLink™ slides (GE Healthcare, UK).
Protocols used for the hybridization and washing proce-
dures have been previously described [37,61]. Image cap-
ture and analysis was performed using the axon 4000B
Scanner and GenePix 6 image analysis software. For all
clones on the array the average, standard deviation and
coefficient of variation (CV) for each of the 4 replicas was
calculated. Clones displaying a CV above 5% between a
minimum of 3 replica spots were discarded from further
analysis. Array-CGH profiles are plotted in Microsoft Excel
with the clone IDs on the X-axis and the normalized fluo-
rescent ratio intensities on the y-axis. The average fluores-BMC Genomics 2007, 8:16 http://www.biomedcentral.com/1471-2164/8/16
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cent ratio value for a given set of continuous clones on the
array is referred to as the Average Normalized Inter Locus
Fluorescence Ratio or ANILFR value.
PCR and sequencing
Exons and conserved non-genic sequences (CNGs) in the
NF2  locus were PCR amplified from genomic DNA
derived from one hundred sporadic meningiomas, with
customized primers using Ampli Taq Gold (Applied Bio-
systems) (primer list in Additional file 4). Peripheral
blood DNA from phenotypically normal control persons
was also PCR amplified and sequenced for CNGs in which
mutations were observed. PCR fragments were purified by
Exosapit (GE Healthcare, UK) digestion prior to sequenc-
ing. Sequencing of amplicons was performed with cus-
tomized nested primers using ET Terminator (GE
Healthcare, UK) and Big Dye v.3.1 (Applied Biosystems)
sequencing chemistries, and ethanol precipitated accord-
ing to standard protocol [59]. Electrophoresis and fluores-
cent detection was carried out on Megabace 1000 (GE
Healthcare, UK) and ABI 3700 (Applied Biosystems) cap-
illary sequencing machines. Processing and analysis of
sequencing data was performed using the Staden package
[62].
Methylation profiling by pyrosequencing of bisulfite 
treated DNA
Pyrosequencing (Biotage, Uppsala, Sweden) was used as
method for detection of methylation of cytosines situated
5'of a guanine [53]. Briefly, the DNA was bisulfite treated
using EZ-96 DNA methylation kit (Zymo research,
Orange, CA, USA) for conversion of unmethylated
cytosines into uracils. In the subsequent PCR uracil ampli-
fies as thymidine. Methylated cytosines remain
unchanged after treatment. Cytosines not followed by a
guanine are not methylated and will therefore be con-
verted to a thymidine after bisulfite treatment and PCR.
These thymidines were used as internal controls for the
completeness of bisulfite treatment. Human genomic
DNA was methylated in vitro by the CpG methylase M. Sss
I and used as positive controls for detection of methyla-
tion. Bisulfite treated DNA were amplified in a 50 µl reac-
tion using Platinum Taq DNA polymerase (Invitrogen Life
Technologies, Carlsbad, CA, USA) according to manufac-
turers protocol. Primers for amplification and sequencing
were custom designed using PSQ assay design software
(Biotage, Uppsala, Sweden). Data of primers used for
amplification and sequencing, as well as the nucleotide
sequence analyzed and the dispensation order of nucle-
otides during sequencing is shown in Additional file 2.
One PCR primer in each pair was biotinylated for conver-
sion of the PCR product to a single stranded template. The
cycling condition used were: 94°C for 3 minutes, fol-
lowed by 20 cycles of 94°C for 20 seconds, 65°C minus
0.5°C/cycle for 20 seconds, 72°C for 1 minute, followed
by 40 cycles of 94°C for 20 seconds, 55°C for 20 seconds,
72°C for 1 minute and finally 72°C for 10 minutes. 45 µl
of PCR product was used for the Pyrosequencing reaction.
Sequencing was performed on a PSQ 96MA system with
PSQ Gold reagent kit (Biotage, Uppsala, Sweden) accord-
ing to manufacturer's protocol. Pyro Q-CpG software
(Biotage, Uppsala, Sweden) was used for data analysis.
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